Risk of Thromboembolism in Heart Failure
- 22 May 2007
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 115 (20), 2637-2641
- https://doi.org/10.1161/circulationaha.106.661397
Abstract
Background— In patients with heart failure, rates of clinically apparent stroke range from 1.3% to 3.5% per year. Little is known about the incidence and risk factors in the absence of atrial fibrillation. In the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), 2521 patients with moderate heart failure were randomized to receive amiodarone, implanted cardioverter-defibrillators (ICDs), or placebo. Methods and Results— We determined the incidence of stroke or peripheral or pulmonary embolism in patients with no history of atrial fibrillation (n=2114), predictors of thromboembolism and the relationship to left ventricular ejection fraction. Median follow-up was 45.5 months. Kaplan-Meier estimates (95% CIs) for the incidence of thromboembolism by 4 years were 4.0% (3.0% to 4.9%), with 2.6% (1.1% to 4.1%) in patients randomized to amiodarone, 3.2% (1.8% to 4.7%) in patients randomized to ICD, and 6.0% (4.0% to 8.0%) in patients randomized to placebo (approximate rates of 0.7%, 0.8%, and 1.5% per year, respectively). By multivariable analysis, hypertension ( P =0.021) and decreasing left ventricular ejection fraction ( P =0.023) were significant predictors of thromboembolism; treatment with amiodarone or ICD treatment was a significant predictor of thromboembolism-free survival ( P =0.014 for treatment effect; hazard ratio [95% CI] versus placebo, 0.57 [0.33 to 0.99] for ICD; 0.44 [0.24 to 0.80] for amiodarone). Inclusion of atrial fibrillation during follow-up in the multivariable model did not affect the significance of treatment assignment as a predictor of thromboembolism. Conclusions— In the SCD-HeFT patient cohort, which reflects contemporary treatment of patients with moderately symptomatic systolic heart failure, patients experienced thromboembolism events at a rate of 1.7% per year without antiarrhythmic therapy. Those treated with amiodarone or ICDs had lower risk of thromboembolism than those given placebo. Hypertension at baseline and lower ejection fraction were independent predictors of risk.Keywords
This publication has 10 references indexed in Scilit:
- Silent Cerebral Infarction in Heart Failure: Vascular or Thromboembolic?Journal of Cardiac Failure, 2005
- Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart FailureNew England Journal of Medicine, 2005
- Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failureEuropean Heart Journal, 2000
- Amiodarone to Prevent Recurrence of Atrial FibrillationNew England Journal of Medicine, 2000
- Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trialsJournal of the American College of Cardiology, 1998
- Ejection Fraction and Risk of Thromboembolic Events in Patients With Systolic Dysfunction and Sinus Rhythm: Evidence for Gender Differences in the Studies of Left Ventricular Dysfunction TrialsJournal of the American College of Cardiology, 1997
- Ventricular Dysfunction and the Risk of Stroke after Myocardial InfarctionNew England Journal of Medicine, 1997
- Low incidence of stroke in ambulatory patients with heart failure: A prospective studyAmerican Heart Journal, 1993
- Fat-suppressed breath-hold magnetic resonance coronary angiography.Circulation, 1993
- The natural history of idiopathic dilated cardiomyopathyThe American Journal of Cardiology, 1981